5-methyl-5-(3-pyrimidin-5-ylphenyl)-5,6-dihydro-2H-[1,4]oxazin-3-ylamine | 1352415-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-methyl-5-(3-pyrimidin-5-ylphenyl)-5,6-dihydro-2H-[1,4]oxazin-3-ylamine
• 英文别名: 5-Methyl-5-(3-pyrimidin-5-ylphenyl)-2,6-dihydro-1,4-oxazin-3-amine
• CAS: 1352415-44-1
• 化学式: C₁₅H₁₆N₄O
• 分子量: 268.318
• InChiKey: YUSMYCUJOJEXRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  73.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)<br/>[FR] DÉRIVÉS DE 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YLAMINE UTILES COMME INHIBITEURS DE BÊTA-SÉCRÉTASE (BACE)
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011154431A1

  公开（公告）日：2011-12-15

  The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta- amyloid.

  本发明涉及新型5,6-二氢-2H-[1,4]噁唑啉-3-胺衍生物，作为β-分泌酶抑制剂，也被称为β-位点淀粉样蛋白裂解酶、BACE、BACE1、Asp2或memapsin2。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及用于预防和治疗涉及β-分泌酶的疾病的这些化合物和组合物的用途，如阿尔茨海默病（AD）、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、唐氏综合征、与中风相关的痴呆、与帕金森病相关的痴呆以及与β-淀粉样蛋白相关的痴呆。
• 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS
  申请人：Andreini Matteo

  公开号：US20120196863A1

  公开（公告）日：2012-08-02

  The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明提供了具有BACE1和/或BACE2抑制活性的式I的1,4噁嗪，以及它们的制备方法、含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病等疾病中是有用的。
• 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2580200B1

  公开（公告）日：2016-09-14
• US8399459B2
  申请人：——

  公开号：US8399459B2

  公开（公告）日：2013-03-19
• US9828350B2
  申请人：——

  公开号：US9828350B2

  公开（公告）日：2017-11-28